Breathing Simulation Testing

Inhalation Science

Programmable breathing simulators with adult and pediatric mouth/nose fixtures — dose collected with cascade impactors or filters and quantified by HPLC, ELISA, or ddPCR per study.

Purpose & when to use

Breathing Simulation Testing uses a programmable pump to replicate human inhalation profiles — tidal volume, flow rate, and breath duration — while quantifying inhaled and respirable dose delivered through a device interface. Compendial configurations align to USP <601> and USP <1601>; adult and pediatric profiles are programmable to ISO 27427 and FDA MDI / DPI / nasal guidance framing. Breathing simulation is used for:

Inhaled dose comparisons across MDIs, DPIs, nebulizers, and soft-mist inhalers — profile-resolved dose datasets aligned to USP <601> and FDA MDI / DPI / nasal guidance for submission and change-control packages.
Pediatric-to-adult profile mapping for inhalation and intranasal products — bracketing use-condition variability across age-scaled tidal volumes and flow rates under FDA pediatric-study guidance.
Mask and valved holding chamber (VHC) interface-effect studies — quantifying leakage, dead-space, and coordination impacts under ISO 27427 nebulizing-equipment and FDA MDI / DPI guidance framing.
Respirable-fraction estimation by pairing breathing simulation with [cascade impactor PSD](/testing-services/particle-aerosol-measurement/psd-testing/) — links device emissions to predicted lung deposition under USP <601> aerodynamic-size framing.
Sensitivity and profile-variability mapping across breathing conditions, actuation timing, and device orientation — supports ICH Q9 risk-assessment and FDA change-control packages.

Use breathing simulation when you need inhaled-dose data tied to realistic use conditions — pediatric or adult profiles, interface variability, or comparison across devices — and the dataset must support an engineering decision, a regulatory submission, or a risk-assessment package.

Built for inhalation and intranasal drug delivery devices

Breathing simulation characterises performance across the device classes where realistic use conditions — patient breathing pattern, interface geometry, and actuation timing — drive the dose the patient receives.

MDIMetered-dose inhalers
DPIDry-powder inhalers
NebulizerLiquid aerosol generators
Nasal sprayIntranasal pump delivery
Spacer / VHCValved holding chambers

Instrumentation & measurement ranges

Platform selection follows the device class, the breathing profile, and the regulatory frame — components are confirmed at study planning and logged in the method report.

5 – 100 L/mininhalation-flow

Programmable breathing simulator (ASL 5000 or equivalent)

Piston-driven breathing pump with programmable tidal volume, flow rate, and breath duration — adult and pediatric profiles selectable; profile fidelity verified against the set waveform before each campaign.

0.1 – 5 sinhalation-duration

Adult and pediatric mouth/nose fixtures and headforms

USP-geometry induction ports, adult/pediatric nose-throat models, and headform-style interfaces — geometry matched to the device class and the patient population under study.

0.4 – 11 µmaerodynamic

Cascade impactors and filter-based collection (NGI / Andersen)

Downstream dose collection via NGI or Andersen cascade impactor stages, or a validated filter assembly — collection method selected to match the size-fraction and dose endpoint required.

0.1 – 1000 µgper-profile

Analytical quantitation suite (HPLC, ELISA, qPCR / ddPCR)

HPLC for small-molecule actives, ELISA for protein analytes, and qPCR / ddPCR for nucleic-acid actives — assay matched to the active and matrix, with system suitability and recovery documented per assay.

Test method options

Method	Strengths	Tradeoff	Aligned with
Compendial-aligned breathing simulation (USP <601> / <1601>)	Submission-grade inhaled-dose datasets under defined fixtures and breathing profiles — the canonical USP <601> and USP <1601> compendial package for inhalation characterisation. Documented acceptance logic and statistical framing for FDA MDI / DPI / nasal submissions, lifecycle changes, and predicate comparisons.	Strict configuration control and documentation overhead — best when device and formulation are locked enough to justify the filing-bound setup cost.	USP <601>USP <1601>FDA MDI / DPI / nasal
Interface and mask effects study (fixture sweep)	Directly measures mask, spacer, and VHC leakage effects on inhaled dose — answers the interface-sensitivity question FDA MDI / DPI guidance requires. Controlled fixture protocol surfaces dose differences attributable to interface geometry alone, isolating interface impact from device variability.	Careful fixture fabrication and leak-check protocol needed to avoid measurement artifacts that obscure real interface effects.	FDA MDI / DPI / nasalISO 27427
User-variability mapping (breathing profile sweep)	Brackets realistic breathing-pattern variability from pediatric low-flow to adult high-flow profiles — supports ICH Q9 risk-assessment and FDA change-control packages. Profile-resolved dose dataset directly informs device-label guidance (optimal flow rate, coordination requirements) and user-group selection rationale.	More profiles increase replicate count and study duration — scope tightly to the profile range that drives the specific decision.	ICH Q9FDA MDI / DPI / nasal
Emissions-to-exposure translation (fit for purpose)	Links device emissions to breathing-zone inhaled dose under defined scenarios — supports exposure assessment beyond the compendial collection endpoint. Pairs with emitted-dose data to build a full dose-to-patient picture; framing aligned to FDA CMC guidance for consumer and medical devices.	Requires explicit scenario definition and documented assumptions — results are scenario-specific and must be scoped carefully to avoid over-generalisation.	FDA MDI / DPI / nasal

Setup configurations

Every breathing simulation study runs on a configuration matched to the device, the patient population, and the regulatory frame. Fit-for-purpose setup balances profile fidelity — correct tidal volume, flow rate, and breath duration — with practical realities of the collection train and quantitation method. The dimensions below are the levers confirmed at study planning:

Device interfaces

Mouthpiece adapters, USP induction ports, adult/pediatric nose-throat models, and headform interfaces — geometry matched to the device class and the target patient population.

Flow & actuation profiles

Programmable tidal volume, peak flow rate, and inhalation duration — adult and pediatric waveforms logged against the set profile before each campaign with actuation timing synchronised to breath phase.

Sample numbers

Replicates per device and per profile — power sized to declared within-profile and device-to-device variability with documented statistical framing.

Media & handling

Collection-media selection (filter or impactor stages), extraction-solvent compatibility, and documented storage and chain of custody for collected fractions.

Environmental controls

Temperature and humidity conditioning when formulation or device performance is known to be sensitive — equilibration and environmental monitoring logged alongside dose collection.

Compliance frame for inhalation breathing simulation

Every breathing simulation study runs inside a documented quality system anchored to the pharmacopoeial and regulatory frames governing inhalation and intranasal products. The four anchors below define the data contract carried through §7 outputs.

ISO 17025AccreditedTesting-laboratory competence — documented methods, calibration traceability, and uncertainty contributors.
USP <601>AccreditedInhalation and nasal drug products — performance quality tests with breathing-simulation provisions.
USP <1601>AlignedProducts for nebulization — characterization tests including breathing-simulator methods.
FDA MDI / DPI / nasalAlignedChemistry, manufacturing, and controls plus breathing-pattern testing for inhalation submissions.

Key data outputs & reporting

Every breathing simulation study delivers inhaled-dose results by profile and condition, repeatability statistics, and the underlying datasets — formatted for submission packages, change-control documentation, or engineering decisions. Profile-resolved dose data, interface-sensitivity comparisons, and respirable-fraction context are the primary deliverables. Traceable QA / QC controls — profile verification logs, fixture leak checks, and assay calibration records — are documented throughout and shipped with every report.

Primary outputs

Inhaled and respirable dose by breathing profile and condition — mean, SD, and CV across replicates, with profile-to-profile comparisons.
Interface sensitivity data — dose delta attributable to mask, spacer, or VHC geometry, with documented fixture-leak controls.
Assay calibration, recovery, and uncertainty contributors documented alongside results for inspection-readiness.

Deliverables

#	Format	Contents
01	PDF report	Methods, breathing-profile setup, controls, statistical framing, and acceptance logic.
02	CSV / XLSX datasets	Per-profile inhaled dose, replicate statistics, and condition deltas.
03	Figures	Dose-versus-profile plots, condition overlays, and interface-sensitivity charts for internal review and submission appendices.

QA / QC & data integrity

Every breathing simulation study ships with a documented QA / QC envelope sized to the method plan — controls and verifications calibrated to the profile fidelity, the collection train, and the analytical method. Checks run alongside dose collection, audited under our ISO 17025 quality system and traceable from sample receipt through final result.

Profile verification logs — breathing-simulator waveform confirmed against the set tidal volume, flow rate, and duration before each campaign and between condition blocks.

Fixture leak checks before and after each collection series — documented to bound leakage contribution to dose uncertainty.

Blanks and background controls for collection media, with stage and filter blanks run alongside device measurements.

Assay controls — calibration standards, system suitability per assay, and spike-recovery on matrix-challenging analytes across HPLC, ELISA, and ddPCR endpoints.

Chain of custody from sample receipt through collection, extraction, quantitation, and final reporting.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)

17025Accredited testing

900+Studies Performed

17+Years in operation

300+Clients supported

Common questions

Quick answers to the questions inhalation and intranasal product teams ask most often when scoping a breathing simulation study — profile selection, pediatric testing, interface effects, quantitation, and deliverables. The answers below are starting points; reach out if your device class, patient population, or regulatory frame doesn't match what's here, since most breathing simulation studies need at least one custom configuration decision that's easier to scope on a call.

Q.Can you run pediatric and adult breathing profiles in the same study?

A.Yes. We program adult and pediatric profiles in the same campaign and report profile-specific dose metrics, so the same physical device campaign yields the age-bracketed dataset needed for pediatric regulatory submissions.

Q.How do you measure inhaled dose from the breathing simulator?

A.Dose is collected downstream of the mouth/nose interface using a filter or cascade impactor, then quantified by HPLC, ELISA, or ddPCR matched to the active and matrix — controls, blanks, and recovery documented per assay.

Q.Can you evaluate mask and spacer interface effects?

A.Yes. Mask and VHC effects are a common study objective. We run controlled fixture sweeps with documented leak checks and report dose delta attributable to interface geometry, not device variability.

Q.Is breathing simulation only for pharmaceutical products?

A.No. It also quantifies inhaled dose for consumer and medical devices where realistic breathing conditions affect the exposure picture — the same simulator and collection methodology, framed for the relevant regulatory or engineering decision.

Q.What do I receive at the end of the study?

A.A PDF report with setup assumptions, profile logs, controls, and statistical framing; CSV / XLSX datasets for per-profile dose and replicate statistics; and figures showing dose versus profile and condition overlays.

Standards & guidance

Breathing simulation studies at ARE Labs run aligned to the pharmacopoeial, consensus, and regulatory standards governing inhaler characterisation and inhalation product submissions. Where we hold third-party accreditation for a scope, methods are documented as accredited (ISO 17025, USP <601>); where the standard is followed but not formally accredited, methods are aligned or conformant where applicable. The cards below list the standards most often relevant to breathing simulation packages.

Inhalation & Drug Delivery - Accredited

Related services & devices

Service